Vividion Therapeutics (Acquired)

The post Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial appeared first on Vividion Therapeutics.

Phase 1 findings reinforce the potential of WRN inhibition as a synthetic lethal approach to treating MSI-high cancers Among efficacy-evaluable patients with MSI-high colorectal cancer, VVD-214 demonstrated an 80.5% disease control rate and median progres

Werner syndrome helicase (WRN) is a synthetic lethal target for microsatellite instability (MSI) cancers. In part 1 of this ongoing first-in-human, phase 1 trial, escalating doses of RO7589831 (VVD-133214), a first-in-class, WRN covalent inhibitor, were e

VVD-214 targets Werner helicase (WRN), a synthetic lethal vulnerability in cancers with high microsatellite instability (MSI-high) or deficient mismatch repair (dMMR) Global Phase Ib clinical study will evaluate VVD-214 in patients with previously treated

The post Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High Cancers appeared first on Vividion Therapeutics.

Manuscript featured on the cover of leading chemistry journal describes the discovery of Vividion's covalent WRN inhibitor VVD-214, now in Phase I clinical trial In preclinical studies, VVD-214 was well tolerated and led to robust tumor regression in mult

Study reveals novel mechanism that activates KEAP1 to drive NRF2 degradation, overcoming a longstanding barrier in targeting NRF2-driven tumors Preclinical data show antitumor activity and enhanced sensitivity to chemotherapies and radiotherapy across mul

The post A covalent allosteric molecular glue suppresses NRF2-dependent cancer growth appeared first on Vividion Therapeutics.

The post Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2 appeared first on Vividion Therapeutics.